Jim Fong joined CTI BioPharma in 2008 as Vice President, Commercial Operations to lead the US commercialization efforts for ZEVALIN and pre-launch activities of PIXUVRI. In 2012, he was promoted to EU General Manager tasked with the commercialization and launch of PIXUVRI in the European Union and in 2015, transitioned to head the US pre-launch efforts for Pacritinib. In 2017, Mr. Fong was promoted to Senior Vice President, Global Operations and CTILS EU General Manager.
Mr. Fong has 30+ years of global commercial operations experience and most recently was National Sales Director at CV Therapeutics where he led a 250 person sales team in the successful Launch of RANEXA. At CV Therapeutics he also held the key leadership positions of director of marketing, sales operations and training. Previously, Mr. Fong has had roles of increasing responsibility while at Daiichi Sankyo and Pharmacia Upjohn primarily focused on sales leadership and market access across the therapeutic areas of oncology, metabolic, CV and psychiatry. He received his Bachelor of Arts degree in Psychology from UCLA.